Intelligent Bio Solutions (INBS) announced the launch of a validation study aimed at significantly reducing the analysis time of its Intelligent Fingerprinting Drug Screening System, IFDSS. The study aims to improve the already rapid time-to-result of INBS’s drug screening technology, which collects samples in under a minute and provides results within ten minutes at the point of collection. Faster results will enable INBS to target the global roadside drug testing market with a first-in-class solution. “Speed matters in drug screening and is critical for roadside law enforcement,” said Harry Simeonidis, President and CEO at INBS. “Moving from a ten-minute test to under three minutes changes the entire value equation for our customers. This validation study aims to confirm our encouraging preliminary findings and advance us toward our two-minute test goal.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INBS:
- Intelligent Bio Solutions Updates Investor Presentation and Share Count
- Intelligent Bio Solutions announces completion of penetrating testing
- Intelligent Bio completes initial drug screening system clinical cut-off study
- Intelligent Bio Solutions Grants Equity Awards, Updates ATM Capacity
- Intelligent Bio Solutions Expands Manufacturing Capacity and Deployment
